Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Robert Casquejo

Physician Assistant, Medical Scottsdale, AZ Physician Assistant

NPI 1043317050 CMS profile 10531886

10900 N Scottsdale Rd, Ste 506, Scottsdale, AZ 85254

Open in the dashboard

General payments

$473,666

1,587 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Casquejo of Scottsdale, AZ is reported in the CMS Open Payments database as having received $473,666 across 1,587 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103,155 346
2024 General $119,996 363
2023 General $123,831 355
2022 General $89,211 308
2021 General $37,472 215

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Casquejo
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Robert Casquejo were reported at $103,155. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Robert Casquejo Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $37,472 $156 $41–$563 $132
2022 $89,211 $185 $55–$649 $149
2023 $123,831 $199 $58–$717 $160
2024 $119,996 $206 $62–$740 $164
2025 $103,155 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $148,526 307 payments
  2. AbbVie, Inc. $75,061 217 payments
  3. Lilly USA, LLC $69,890 202 payments
  4. Arcutis Biotherapeutics, Inc. $55,109 134 payments
  5. Incyte Corporation $40,171 115 payments
  6. E.R. Squibb & Sons, L.L.C. $28,397 82 payments
  7. UCB, Inc. $13,527 106 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $8,162 59 payments
  9. Novartis Pharmaceuticals Corporation $7,038 43 payments
  10. Eli Lilly and Company $5,717 7 payments
  11. Other $22,067 315 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $260,365 216 payments
  2. Travel and Lodging $96,326 304 payments
  3. Consulting Fee $64,168 45 payments
  4. Food and Beverage $42,774 1,007 payments
  5. Debt forgiveness $5,270 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $4,050 2 payments
  7. Education $713 12 payments
Products named General payments · program years 2021–2025
  1. Otezla $131,148 279 payments
  2. SKYRIZI Immunology $54,019 135 payments
  3. OPZELURA $39,135 113 payments
  4. Zoryve $37,079 93 payments
  5. TALTZ $24,785 82 payments
  6. SOTYKTU $21,884 67 payments
  7. EBGLYSS $16,143 50 payments
  8. RINVOQ $10,690 36 payments
  9. SKYRIZI Immunology $8,986 33 payments
  10. Cimzia $8,932 86 payments
  11. Other $38,684 590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

374

Median for Physician Assistant: 241

Drug cost

$139,692

Median for Physician Assistant: $4,110

Branded share of claims

7.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 12 $130,787
Clobetasol Propionate Generic 76 $4,183
Valacyclovir Valacyclovir Hcl Brand 17 $980
Ketoconazole Generic 37 $819
Fluorouracil Generic 18 $782
Metronidazole Generic 20 $656
Clindamycin Phosphate Generic 17 $501
Hydrocortisone Generic 54 $327
Triamcinolone Acetonide Generic 72 $318
Doxycycline Hyclate Generic 17 $182

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$1,112,792

Of which drugs: $865,028

Medicare patients

435

Average age 76

Services billed

9,779

190 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Ischemic heart disease 30%
Atrial fibrillation 18%
Cancer 17%
Diabetes 15%
Chronic kidney disease 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Restorigin, per square centimeter Q4191 Office 27 282 $337,751
Xcell amnio matrix, per square centimeter Q4280 Office 17 162 $201,943
Complete ft, per square centimeter Q4271 Office 24 152 $179,660
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 22 6,200 $8,184

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
$40,499 — —
SKYRIZI
$27,388 — —
Zoryve
$20,573 — —
OPZELURA
$7,246 — —
TALTZ
$2,919 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,587 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record